Terns Pharmaceuticals
Akero fails to meet NASH trial endpoint, hurting other players in the field
Anika Sharma
The landscape of Nonalcoholic Steatohepatitis (NASH) appeared promising with Madrigal Therapeutics taking steps toward treatment approval. However, this optimism was ...
